Exchange Traded Concepts LLC Boosts Holdings in Boston Scientific Corporation $BSX

Exchange Traded Concepts LLC increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 54.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 64,663 shares of the medical equipment provider’s stock after buying an additional 22,791 shares during the period. Exchange Traded Concepts LLC’s holdings in Boston Scientific were worth $6,313,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in BSX. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth $26,000. Sound Income Strategies LLC raised its position in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. Steph & Co. purchased a new position in shares of Boston Scientific in the 3rd quarter valued at about $25,000. 1248 Management LLC acquired a new position in shares of Boston Scientific during the first quarter worth about $26,000. Finally, Kilter Group LLC purchased a new stake in shares of Boston Scientific during the second quarter worth approximately $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

NYSE BSX opened at $96.05 on Wednesday. The company has a fifty day moving average of $98.67 and a two-hundred day moving average of $101.17. The company has a market capitalization of $142.38 billion, a PE ratio of 51.36, a P/E/G ratio of 1.94 and a beta of 0.67. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the subject of a number of recent research reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. BTIG Research reaffirmed a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Friday, November 21st. Barclays boosted their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. UBS Group restated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Finally, Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $124.85.

Insider Activity

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 143,095 shares of company stock valued at $14,228,950. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.